Enhancement of immune responses by nanoparticle-based vaccination against respiratory syncytial virus

Summarise with VIRAT
Authors: Alison J. Lin
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease in infants and elderly individuals, populations for whom effective vaccination remains challenging due to age-related immune limitations. This thesis aimed to develop innovative vaccine strategies to enhance humoral immune responses against RSV. To achieve this objective, several vaccine platforms were evaluated: (1) co display of SH and F glycoproteins on the I53-50 nanoparticle to investigate the role of SH in RSV infection and immunity, (2) co-display of F-RSV with a co-immunomodulator that promotes B cell activation, and (3) fusion of F-RSV with a co-immunomodulator. Nanoparticle-displayed F-RSV generated robust neutralizing antibody responses and activated distinct immune transcription programs compared to the trimeric antigen. Co display of SH with F-RSV increased F-specific IgG responses and enhanced neutralizing activity against the RSV-A2 strain, while the addition of APRIL further improved antibody potency. Fusion of F-RSV with IL-21 produced neutralizing activity comparable to nanoparticle-based platforms, increased F-specific IgG titers, and induced antibodies targeting antigenic sites IV and V, which are associated with potent neutralizing responses. In summary, this research demonstrates that integrating multivalent antigen presentation with immunomodulatory approaches or inclusion of the SH protein can enhance humoral immunity against RSV. SH-specific antibodies may facilitate antibody-dependent cellular cytotoxicity and complement the neutralizing activity of F specific antibodies. Furthermore, fusion of F-RSV with IL-21 may promote B cell activation and improve antigen presentation. These findings offer important insights for the development of next-generation RSV vaccines designed for vulnerable populations.

Fields of Study & Subjects

Respiratory viral infections research SARS-CoV-2 and COVID-19 Research Virology and Viral Diseases

Publication details

Journal / source
IRIS
Publication date
5 March 2026
Language
EN
Document type
Thesis